drugmakers

Korean stock market Samsung Biologics shares fly high to be Korea’s third most valuable firm

Samsung Biologics Co., the world’s largest contract drugmaker, has become South Korea’s third most valuable stock on the country’s...

Earnings Samsung Biologics posts record 2024 sales, operating profit as it goes global

South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating p...

Bio & Pharma Korean drugmakers control more than half of European biosimilar market

South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...

Bio & Pharma Daewoong wins permission for Nabota in Argentina

South Korea's Daewoong Pharmaceutical Co. announced on Monday that its botulinum toxin Nabota received product approval from Argentina's National Ad...

Bio & Pharma S.Korean anti-obesity drugmakers eye niche demand

The global weight management market has entered a new chapter following the arrival of blockbuster weight-loss medication Wegovy, and South Korean l...

Bio & Pharma Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Bio & Pharma Samsung Biologics eyes new drugmaker acquisitions

BARCELONA -- Samsung Biologics Co., the world’s top contract manufacturing organization by capacity, is looking for acquisitions of new drugma...

Bio & Pharma Celltrion’s approved merger removes hurdle to three-way combination

South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...

Bio & Pharma IMM PE seeks to sell Korean contract drugmaker at $784 mn

IMM Private Equity has put a South Korean contract drugmaker on the market for up to 1 trillion won ($784 million) in a deal likely to attract major...

Bio & Pharma Samsung Biologics wins $897 mn in two deals with Pfizer

Samsung Biologics Co., the world’s largest contract manufacturing organization (CMO) in terms of production capacity, said on Tuesday it has w...

Bio & Pharma LegoChem Bio receives FDA approval for phase 1,2 trials of LCB84

South Korean pharmaceutical firm LegoChem Biosciences Inc. announced on Thursday that it has received approval from the US Food and Drug Administrat...

Bio & Pharma Daewoong Pharma wins permission from Singapore for Nabota

South Korea's drug development company Daewoong Pharmaceutical said on Thursday that it received on Jan. 20 product approval for its botulinum toxin...

Bio & Pharma JW Pharma to put AI into new drug ingredient development

South Korea's drug developer JW Pharmaceutical is expanding the scope of its artificial intelligence (AI) uses from new drug research to the develop...

Bio & Pharma Celltrion increases its stake in British ADC developer Iksuda

Celltrion Inc. has secured an additional stake in the UK's antibody-drug conjugate (ADC) developer Iksuda Therapeutics.According to Celltrion on Wed...

Healthcare Celltrion targets digital healthcare sector with app

Celltrion Inc., South Korea’s biopharmaceutical giant, made a foray into the digital healthcare sector for its future growth by launching a sm...

Bio & Pharma Celltrion wins sales approval for biosimilar Vegzelma in Japan

Celltrion Inc. secured Japan’s approval for sales of its cancer treatment biosimilar CT-P16, a move to help the South Korean biopharmaceutical...

Earnings Celltrion logs strong Q2 earnings powered by biosimilars

South Korea’s biopharmaceutical maker Celltrion Inc. on Friday reported strong quarterly earnings thanks to healthy demand for its biosimilar ...

Bio & Pharma Korean drugmakers close to commercializing COVID-19 vaccine, pill

South Korea’s biopharmaceutical companies are close to commercializing a COVID-19 vaccine and treatment pill as they are on the brink of compl...

Bio & Pharma Hanmi stands out with own drugs as Korean rivals sell imports

South Korea’s Hanmi Pharmaceutical Co. generated sales of more than 1 trillion won ($812.3 million) from its own medicines last year on strong...

Pharmaceuticals Samsung Biologics wins another Eli Lilly COVID treatment order

Samsung Biologics Co., a global contract development and manufacturing organization (CDMO), has stepped up its partnerships with global big pharmas ...

Biosimilars Korean drugmakers race to release Stelara biosimilars

South Korea’s major drugmakers such as Celltrion Inc., Samsung Bioepis and Dong-A St are going for broke to release biosimilars of Stelara, Jo...